Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Kodiak Sciences Inc. KOD NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$44.00
-2.4%

Kodiak Sciences Inc. (KOD) is a Biotechnology company in the Healthcare sector, currently trading at $45.07. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is KOD = $44 (-2.4% upside).

Valuation: KOD trades at a trailing Price-to-Earnings (P/E) of -9.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.06.

Net income is $230M (loss), growing at +7.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $59M against $157M equity (Debt-to-Equity (D/E) ratio 0.38, conservative). Current ratio is 4.72 (strong liquidity). Debt-to-assets is 16.8%. Total assets: $352M.

Analyst outlook: 12 / 18 analysts rate KOD as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 58/100 (Partial), Growth 65/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 47/100 (Partial), Income ?/100 (Fail).

$44.00
▼ 2.37% Downside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for Kodiak Sciences Inc., the average price target is $44.00, with a high forecast of $50.00, and a low forecast of $38.00.
Highest Price Target
$50.00
Average Price Target
$44.00
Lowest Price Target
$38.00

KOD SharesGrow Score Overview

62/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 58/100
Valuation — P/E, PEG, Forward PEG
GROWTH 65/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 47/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — KOD

~
VALUE Partial
58/100
KOD trades at a trailing Price-to-Earnings (P/E) of -9.5 (S&P 500 average ~25). Forward PEG 1.06 — ~moderate (~1.5). Trailing PEG 1.95. Analyst consensus target is $44, implying -2.4% from the current price $45. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
65/100
KOD: +0%/yr revenue is, +7.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet KOD: Debt-to-Equity (D/E) ratio 0.38 (conservative), Current ratio is 4.72 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
KOD: Gross margin is 0% (+0 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
47/100
Analyst outlook: 12 / 18 analysts rate KOD as buy (67%). Analyst consensus target is $44 (-2.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.92-45.6
Volume1.24M
Avg Volume (30D)1.09M
Market Cap$2.39B
Beta (1Y)2.40
Share Statistics
EPS (TTM)-4.32
Shares Outstanding$53.21M
IPO Date2018-10-04
Employees109
CEOVictor Perlroth
Financial Highlights & Ratios
EBITDA$-234.39M
Net Income$-229.97M
Operating Income$-234.39M
Total Cash$209.86M
Total Debt$59.18M
Net Debt$-150.68M
Total Assets$351.53M
Price / Earnings (P/E)-10.4
Analyst Forecast
1Y Price Target$44.00
Target High$50.00
Target Low$38.00
Upside-2.4%
Rating ConsensusBuy
Analysts Covering18
Buy 67% Hold 28% Sell 6%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS50015M1099

Price Chart

Track all markets on TradingView
KOD
Kodiak Sciences Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
1.92 52WK RANGE 45.60

People Also View

MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 MRTX
MRTX
Mirati Therapeutics, Inc.
$58.70
-0.17%
 SRPT
SRPT
Sarepta Therapeutics, Inc.
$22.15
+1.65%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 ICPT
ICPT
Intercept Pharmaceuticals, Inc.
$19.00
+0.21%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message